Abciximab following clopidogrel reduces post-PCI complications in patients with acute coronary syndromes

摘要

Percutaneous coronary interventions (PCIs) are established approaches for the treatment of high-risk patients with non-ST-segment elevation acute coronary syndromes (ACS). Clopidogrel given as a 600 mg loading dose before PCI has been shown to reduce post-procedural ischemic complications, but it is unclear whether this regimen provides optimal efficacy or whether there is a need for more-potent antiplatelet therapies in these patients. OBJECTIVE This study aimed to assess whether abciximab, a glycoprotein llb/llla inhibitor, reduces the risk of adverse events in high-risk patients with ACS undergoing PCI after pretreatment with clopidogrel.